Structural and functional changes in the kidneys of high-fat diet-induced obese mice

American Journal of Physiology - Renal Physiology

Volumn 296, Issue 1, 2009, Pages

  Deji, Naoko ^a   Kume, Shinji ^a   Araki, Shin Ichi ^a   Soumura, Mariko ^a   Sugimoto, Toshiro ^a   Isshiki, Keiji ^a   Chin Kanasaki, Masami ^a   Sakaguchi, Masayoshi ^a   Koya, Daisuke ^b   Haneda, Masakazu ^c   Kashiwagi, Atsunori ^a   Uzu, Takashi ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Dietary restriction; Inflammation; Lipotoxicity; Metabolic syndrome; Salt sensitive hypertension

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; COLLAGEN TYPE 4; GLUCOSE; INSULIN; SODIUM; TRIACYLGLYCEROL;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALORIE; CELL INFILTRATION; CONTROLLED STUDY; DIET RESTRICTION; GLOMERULUS; INSULIN BLOOD LEVEL; KIDNEY; KIDNEY HYPERTROPHY; KIDNEY MEDULLA; LIPID DIET; LIPID STORAGE; LOW FAT DIET; MACROPHAGE; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WEIGHT CONTROL;

EID: 58849141672     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00110.2008     Document Type: Article

References (53)

1. Anonymous. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III final report). Circulation 106: 3143-3421, 2002.
2. Barcelli UO, Weiss M, Beach D, Motz A, Thompson B. High linoleic acid diets ameliorate diabetic nephropathy in rats. Am J Kidney Dis 16: 244-251, 1990.
3. Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402: 880-883, 1999.
4. Breyer MD, Bottinger E, Brosius FC 3rd, Coffman TM, Harris RC, Heilig CW, Sharma K. Mouse models of diabetic nephropathy. J Am Soc Nephrol 16: 27-45, 2005.
5. Carey RM, Padia SH. Angiotensin AT2 receptors: control of renal sodium excretion and blood pressure. Trends Endocrinol Metab 19: 84-87, 2008.
6. Carroll L, Voisey J, van Daal A. Mouse models of obesity. Clin Dermatol 22: 345-349, 2004.
7. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140: 167-174, 2004.
8. Diaz Encarnacion MM, Warner GM, Gray CE, Cheng J, Keryakos HK, Nath KA, Grande JP. Signaling pathways modulated by fish oil in salt-sensitive hypertension. Am J Physiol Renal Physiol 294: F1323-F1335, 2008.
9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287: 356-359, 2002.
10. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among us. Adults Diabetes Care 27: 2444-2449, 2004.
11. Fujita A, Sasaki H, Ogawa K, Okamoto K, Matsuno S, Matsumoto E, Furuta H, Nishi M, Nakao T, Tsuno T, Taniguchi H, Nanjo K. Increased gene expression of antioxidant enzymes in KKAy diabetic mice but not in STZ diabetic mice. Diabetes Res Clin Pract 69: 113-119, 2005.
12. Fujita T. Insulin resistance and salt-sensitive hypertension in metabolic syndrome. Nephrol Dial Transplant 22: 3102-3107, 2007.
13. Ge Y, Bagnall A, Stricklett PK, Strait K, Webb DJ, Kotelevtsev Y, Kohan DE. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol 291: F1274-F1280, 2006.
14. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004.
15. Ina K, Kitamura H, Okeda T, Nagai K, Liu ZY, Matsuda M, Fujikura Y. Vascular cell adhesion molecule-1 expression in the renal interstitium of diabetic KKAy mice. Diabetes Res Clin Pract 44: 1-8, 1999.
16. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-689, 2001.
17. Jennette JC, Charles L, Grubb W. Glomerulomegaly and focal segmental glomerulosclerosis associated with obesity and sleep-apnea syndrome. Am J Kidney Dis 10: 470-472, 1987.
18. Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, Lucia MS, Li J, Levi M. Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 280: 32317-32325, 2005.
19. Johnson DW, Armstrong K, Campbell SB, Mudge DW, Hawley CM, Coombes JS, Prins JB, Isbel NM. Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification. Nephrology (Carlton) 12: 391-398, 2007.
20. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59: 1498-1509, 2001.
21. Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med 146: 1105-1109, 1986.
22. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: 659-663, 2004.
23. Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Hyodo N, Suzuki S, Miura S. Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant 20: 1573-1581, 2005.
24. Kimura G, Uzu T, Nakamura S, Inenaga T, Fujii T. High sodium sensitivity and glomerular hypertension/hyperfiltration in primary aldosteronism. J Hypertens 14: 1463-1468, 1996.
25. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 16: 157-177, 1993.
26. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14: 439-447, 2000.
27. Kume S, Uzu T, Araki S, Sugimoto T, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Kubota N, Terauchi Y, Kadowaki T, Haneda M, Kashiwagi A, Koya D. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol 18: 2715-2723, 2007.
28. Kumpers P, Gueler F, Rong S, Mengel M, Tossidou I, Peters I, Haller H, Schiffer M. Leptin is a coactivator of TGF-beta in unilateral ureteral obstructive kidney disease. Am J Physiol Renal Physiol 293: F1355-F1362, 2007.
29. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 16: 2134-2140, 2005.
30. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716, 2002.
31. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 286: 1195-1200, 2001.
32. Ninomiya T, Kiyohara Y, Kubo M, Yonemoto K, Tanizaki Y, Doi Y, Hirakata H, Iida M. Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 48: 383-391, 2006.
33. Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 16: 952-958, 2003.
34. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 18: 1227-1238, 2007.
35. 1 receptors. J Am Soc Nephrol 13: 1131-1135, 2002.
36. Rossmeisl M, Rim JS, Koza RA, Kozak LP. Variation in type 2 diabetes-related traits in mouse strains susceptible to diet-induced obesity. Diabetes 52: 1958-1966, 2003.
37. Sagar S, Kallo IJ, Kaul N, Ganguly NK, Sharma BK. Oxygen free radicals in essential hypertension. Mol Cell Biochem 111: 103-108, 1992.
38. Sharma AM. Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 44: 12-19, 2004.
39. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 284: F1138-F1144, 2003.
40. Sone H, Suzuki H, Takahashi A, Yamada N. Disease model: hyperinsulinemia and insulin resistance. Part A - targeted disruption of insulin signaling or glucose transport. Trends Mol Med 7: 320-322, 2001.
41. Stevens VA, Saad S, Poronnik P, Fenton-Lee CA, Polhill TS, Pollock CA. The role of SGK-1 in angiotensin II-mediated sodium reabsorption in human proximal tubular cells. Nephrol Dial Transplant 23: 1834-1843, 2008.
42. Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 277: 18919-18927, 2002.
43. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37: 1163-1167, 1988.
44. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55: 225-233, 2006.
45. Uzu T, Kimura G, Yamauchi A, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Nishio Y, Maegawa H, Koya D, Haneda M, Kashiwagi A. Enhanced sodium sensitivity and disturbed circadian rhythm of blood pressure in essential hypertension. J Hypertens 24: 1627-1632, 2006.
46. Uzu T, Nishimura M, Fujii T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, Sugiomoto T, Kashiwagi A, Kimura G. Benidipine attenuates glomerular hypertension and reduces albuminuria in patients with metabolic syndrome. Hypertens Res 30: 161-165, 2007.
47. Valles P, Wysocki J, Batlle D. Angiotensin II and renal tubular ion transport. ScienticWorld Journal 5: 680-690, 2005.
48. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 444: 875-880, 2006.
49. Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S, Manning B, Strosberg AD, Stern MP, Raben N. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med 333: 343-347, 1995.
50. Wei P, Lane PH, Lane JT, Padanilam BJ, Sansom SC. Glomerular structural and functional changes in a high-fat diet mouse model of early-stage Type 2 diabetes. Diabetologia 47: 1541-1549, 2004.
51. Weinberg JM. Lipotoxicity. Kidney Int 70: 1560-1566, 2006.
52. West DB, Boozer CN, Moody DL, Atkinson RL. Dietary obesity in nine inbred mouse strains. Am J Physiol Regul Integr Comp Physiol 262: R1025-R1032, 1992.
53. Zoja C, Corna D, Rottoli D, Zanchi C, Abbate M, Remuzzi G. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int 70: 97-103, 2006.